Halozyme Therapeutics shares tumbled Tuesday on a new Medicare approach to price negotiations for drugs that use additive products, like its hyaluronidase. Under the Inflation Reduction Act, the ...

In September 2025, the U.S. Food and Drug Administration (FDA) approved several new cancer therapies and supportive care ...

KEYTRUDA QLEX is indicated for the treatment of adult patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then ...

The FDA approved a subcutaneous formulation of the blockbuster cancer drug pembrolizumab (Keytruda Qlex) for use across the drug's numerous solid tumors indications.

The negotiation program was created by former President Biden’s Inflation Reduction Act, which Democrats passed without a ...

Upon systemic administration, H-NGs utilize the tumor trafficking of CAR-T cells to penetrate tumor tissues, bypassing the tumor vasculature system (Step 1). As the result, H-NGs on the cellular ...

Halozyme Therapeutics (HALO) is a $9 billion biotech focused on oncology and boasting sales and profit growth of 29% and 46%, respectively, while trading a sub-11x forward P/E. HALO is focused on the ...

A recent study published in Life Metabolism has uncovered a surprising new player in the body's ability to regulate blood sugar after eating. Researchers from Baylor College of Medicine and the ...

Johnson & Johnson’s (J&J’s) multiple myeloma combination of Tecvayli (teclistamab-cqyv) and Darzalex Faspro (daratumumab and hyaluronidase-fihj) as an induction treatment has elicited a 100% overall ...